Immunotherapy cocktail takes on tough pancreatic cancer
NCT ID NCT04390399
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding a mix of immune-boosting drugs and special immune cells to standard chemotherapy can help people with advanced pancreatic cancer live longer. About 328 participants will receive either chemo alone or chemo plus the immunotherapy combo. The study aims to see if the combo slows cancer growth and improves quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
combination of N-803 (immune booster), aldoxorubicin (chemotherapy), and PD-L1 t-haNK (immune cells) plus standard chemotherapy
What this could lead to
If successful, this could offer a more effective treatment option for advanced pancreatic cancer, potentially extending survival and improving quality of life.
What could go wrong
This is a mid-stage trial, so results are not yet proven. The combination may cause more side effects than standard chemo, and it may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Astera Cancer Care
East Brunswick, New Jersey, 08816, United States
-
Avera Cancer Institute
Sioux Falls, South Dakota, 57105, United States
-
Chan Soon-Shiong Institute for Medicine
El Segundo, California, 90245, United States
-
Hoag memorial Presbyterian Hospital
Newport Beach, California, 92663, United States